TO PATHOGENETIC SUBSTANTIATION OF PEPTIDE BIOREGULATORS TREATMENT COURSES IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

TheAIM: to clarify the clinical utility and optimal multiplicity and duration of repeated courses of prostatilen treatment in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: We observed 56 patients with BPH aged from 5l to 89 years. 22 of them had the 1st stage of the disease (according to the classification by F. Guyon) and 54 patients - 2nd stage. As a therapeutic agent we used prostatilen in rectal suppositories containing 50 mg with 90 mg Dimexidum (as a conductor). For the course of treatment 15 suppositories were given. Prostatilen treatment was performed every three months - all four courses in one year. The survey included DRE, prostate ultrasound, uroflowmetry with the assessment of the maximum urinary flow rate. Urination quality was evaluated using questionnaires and counted as a sum score by IPSS. RESULTS: During the first course of treatment in patients with decreased frequency of urination with 9,4 ± 1,4 to 5,5 ± 1,1 times a day (p <0.05), the amount of residual urine in the bladder was reduced by more than half, and maximum urinary flow rate increased from 7,9 ± 2,5 to 17,8 ± 1,7 ml/sec (p <0.001). After a year from start of the treatment the examined patients showed significantly increased maximum speed of urination, and residual urine volume decreased compared with baseline. CONCLUSIONS: The treatment of patients with BPH with prostate gland preparations should be considered the most efficient by using small unit doses (5-10 mg per injection or 50 mg rectal suppositories) in short courses of 5-15 days with intervals of 5-4-6 months.

benign prostatic hyperplasia, peptides, prostatilen, pathogenesis, treatment course

1. Хавинсон ВХ, Кузник БИ, Рыжак ГА. Пептидные биорегуляторы - новый класс геропротекторов. Сообщение 1. Результаты экспериментальных исследований. Успехи геронтол 2012; 25(4): 696-798

2. Кузник БИ. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство, 2010; 832

3. Аль-Шукри СХ, Кузьмин ИВ. Опыт применения комплекса пептидов предстательной железы «уропрост» у больных с хроническим простатитом. Материалы Пленума правления Российского общества урологов (Краснодар, 29 сентября - октября 2010). Краснодар, 2010; 324 - 325

4. Аль-Шукри СХ, Бобков ЮА, Горбачев АГидр. Наш опыт применения простатилена в урологии. Урология 2003; 6: 32-36

5. Кузник БИ, Хавинсон ВХ, Морозов ВГидр. Пептидные биорегуляторы: применение в травматологии, хирургии, стоматологии и онкологии. М.: Вузовская книга, 2007; 400

6. Ашмарин ИП, Ещенко НД, Каразеева ЕП. Нейрохимия в таблицах и схемах. М.: Экзамен, 2007; 144

7. Хавинсон ВХ, Анисимов ВН. 35-летний опыт исследований пептидной регуляции старения. Успехи геронтол 2009; 22(1): 11-23